CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal) LABORATORY RESEARCH Tissue Transglutaminase Contributes to the All-Trans Retinoic Acid Induced Differentiation Syndrome Phenotype in the NB4 Model of Acute Promyelocytic Leukemia Researchers propose that reduced expression of transglutaminase 2 in differentiating acute promyelocytic leukemia cells may suppress effector functions of neutrophil granulocytes and attenuate the all-trans -retinoic acid-induced inflammatory phenotype of differentiation syndrome. [Blood] Hedgehog Signaling Maintains Chemoresistance in Myeloid Leukemic Cells In this study, researchers show that the chemotherapy-resistant phenotype of myeloid leukemia cells correlates with activation of the Hedgehog pathway, whereas in chemosensitive cells, such activation is less pronounced. [Oncogene] A Functional SUMO-Interacting Motif in the Transactivation Domain of c-Myb Regulates its Myeloid Transforming Ability Using both a myeloid cell line-based assay and a primary hematopoietic cell assay, researchers addressed the transforming abilities of SUMO binding and conjugation mutants. [Oncogene] Arsenic Trioxide Induces Apoptosis through JNK and ERK in Human Mesothelioma Cells These results indicated that As2O3 induces apoptosis of NCI-H2052 cells mainly through JNK1/2 activation, and that ERK1/2 is involved in As2O3-induced apoptosis when JNK1/2 are inactivated. [J Cell Physiol] Regulation of the PML Tumor Suppressor in Drug-Induced Senescence of Human Normal and Cancer Cells by JAK/STAT-Mediated Signaling Here, researchers show that genotoxic drugs that induce senescence, such as 5-bromo-2’deoxyuridine, thymidine, distamycin A, aphidicolin, etoposide and camptothecin all evoke expansion of Promyelocytic leukemia protein nuclear compartment and its association with persistent DNA lesions in several human cancer cell lines and normal diploid fibroblasts. [Cell Cycle] Prospective Evaluation of Allogeneic Hematopoietic Stem-Cell Transplantation From Matched Related and Matched Unrelated Donors in Younger Adults With High-Risk Acute Myeloid Leukemia: German-Austrian Trial AMLHD98A This study assesses the impact of allogeneic hematopoietic stem-cell transplantation from matched related donors and matched unrelated donors on outcome in high-risk patients with acute myeloid leukemia within a prospective multicenter treatment trial. [J Clin Oncol] Prognosis of Binet Stage A Chronic Lymphocytic Leukemia Patients: The Strength of Routine Parameters Researchers propose an easy, fast, cost-effective strategy for a trustworthy prognostication in stage A patients, who currently represent over 80% of the chronic lymphocytic leukemia population, allowing physicians to adapt follow-up individually. [Blood] Th17 Immune Responses Contribute to the Pathophysiology of Aplastic Anemia Th17 immune responses contribute to aplastic anemia pathohysiology, especially at the early stage during disease progression. [Blood] Treatment of Patients with Relapsed/Refractory Multiple Myeloma with Lenalidomide and Dexamethasone With or Without Bortezomib: Prospective Evaluation of the Impact of Cytogenetic Abnormalities and of Previous Therapies Researchers prospectively studied the impact of several cytogenetic abnormalities in patients with relapsed/refractory myeloma who received lenalidomide and dexamethasone with or without the addition of bortezomib. [Leukemia]
|
|
POLICY NEWS Court Sides With State in Baby Blood Storage Case Minnesota did not violate families’ privacy rights by collecting and storing children’s blood samples, the state Court of Appeals ruled. [Counthouse News Service] NIH Director Collins Says Cell Ruling Won’t Halt Most Ongoing Grants National Institutes of Health (NIH) Director Francis Collins said that the court injunction blocking federally funded research on human embryonic stem cells will not affect grant payments that have already gone out the door this year. [National Institutes of Health, United States] NIH Director’s Response to Stem Cell Injunction [National Institutes of Health, United States] Office of the Director, National Institutes of Health; Notice of Meeting (FR Doc. 2010-20861) [National Institutes of Health, United States] Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-21357) [National Institutes of Health, United States] National Cancer Institute; Notice of Closed Meeting (FR Doc. 2010-21282) [National Institutes of Health, United States] National Human Genome Research Institute; Notice of Closed Meeting (FR Doc. 2010-21317) [National Institutes of Health, United States] National Human Genome Research Institute; Notice of Meetings (FR Doc. 2010-20858) [National Institutes of Health, United States] National Center for Research Resources; Notice of Closed Meeting (FR Doc. 2010-21280) [National Institutes of Health, United States]
|
|
EVENTS (Listed by Date) The European Molecular Biology Organization (EMBO) Meeting 2010 September 4-7, 2010 Barcelona, Spain International Society for Cellular Therapy (ISCT) – Europe 2nd Regional Meeting September 11-14, 2010 Belgirate, Italy Stem Cells USA & Regenerative Medicine Congress 2010 September 13-15, 2010 Philadelphia, United States Society for Hematology and Stem Cells (ISEH) 2010 Meeting September 15-18, 2010 Melbourne, Australia Sickle Cell Disease Association of America (SCDAA) 38th Annual Convention September 21-24, 2010 Washington D.C., United States American Society of Hematology (ASH) State-of-the-Art Symposium 2010 September 24-25, 2010 Chicago, United States Society for the Advancement of Blood Management® (SABM®) 2010 Annual Meeting September 24-26, 2010 San Juan, Puerto Rico Stem Cells and Regeneration October 3-9, 2010 Woods Hole, United States American Association of Blood Banks (AABB) Annual Meeting 2010 October 9-12, 2010 Baltimore, United States Fraunhofer Life Science Symposium Leipzig 2010 October 29-30, 2010 Leipzig, Germany 52nd American Society of Hematology (ASH) Annual Meeting and Exposition December 4-7, 2010 Orlando, United States Highlights of American Society of Hematology (ASH) Vancouver January 21-22, 2011 Vancouver, Canada Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community. JOB OPPORTUNITIES
Cell Therapy Technologist (Opexa Therapeutics) Recruit Top Talent Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News. Visit here to post your career opportunities. Have we missed an important article or publication in Hematopoiesis News? Click here to submit! Comments or Suggestions? Email info@connexoncreative.com with your feedback. |
| |
|